Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

Cediranib, a pan-vascular endothelial growth factor receptor inhibitor, suppresses expression of homologous recombination repair (HRR) genes and increases sensitivity to poly-(ADP-ribose) polymerase inhibition in preclinical models. We investigated whether cediranib combined with olaparib improves t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joseph W., McKay, Rana R., Radke, Marc R., Zhao, Shilin, Taplin, Mary-Ellen, Davis, Nancy B., Monk, Paul, Appleman, Leonard J., Lara, Primo N., Vaishampayan, Ulka N., Zhang, Jingsong, Paul, Asit K., Bubley, Glenn, Van Allen, Eliezer M., Unlu, Serhan, Huang, Ying, Loda, Massimo, Shapiro, Geoffrey I., Glazer, Peter M., LoRusso, Patricia M., Ivy, S. Percy, Shyr, Yu, Swisher, Elizabeth M., Petrylak, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901975/
https://www.ncbi.nlm.nih.gov/pubmed/36256912
http://dx.doi.org/10.1200/JCO.21.02947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901975/
https://www.ncbi.nlm.nih.gov/pubmed/36256912
http://dx.doi.org/10.1200/JCO.21.02947

Ejemplares similares